MAPK3
MAPK3 (Mitogen-activated protein kinase 3) is a protein kinase, an enzyme that switches other proteins on by adding phosphate groups. The public catalogues list it as a drug target, and clinical evidence ties its variants to diagnosis, prognosis or drug response.
Overview
Serine/threonine kinase which acts as an essential component of the MAP kinase signal transduction pathway. MAPK1/ERK2 and MAPK3/ERK1 are the 2 MAPKs which play an important role in the MAPK/ERK cascade. They participate also in a signalling cascade initiated by activated KIT and KITLG/SCF.
Open Targets scores its association with cancer at 0.63 (direct and indirect evidence; datatypes literature 0.99, affected pathway 0.97, genetic association 0.00, clinical 0.19).
- Target · the protein and the cell it sits on
- Drug · antibody, small molecule, cell or radioligand
- Effect · signal, damage or kill
In plain words · MAPK3 (Mitogen-activated protein kinase 3) is a protein kinase, an enzyme that switches other proteins on by adding phosphate groups. The public catalogues list it as a drug target, and clinical evidence ties its variants to diagnosis, prognosis or drug response.
- 1 · What it is
MAPK3 (Mitogen-activated protein kinase 3) is a protein kinase, an enzyme that switches other proteins on by adding phosphate groups. The public catalogues list it as a drug target, and clinical evidence ties its variants to diagnosis, prognosis or drug response.
- 2 · What goes wrong in cancer
Serine/threonine kinase which acts as an essential component of the MAP kinase signal transduction pathway. MAPK1/ERK2 and MAPK3/ERK1 are the 2 MAPKs which play an important role in the MAPK/ERK cascade.
- 3 · How drugs use it
No product in this corpus aims at MAPK3 yet. Kinases are switched on by binding ATP inside the cell, so most drugs are small molecules shaped to plug that ATP pocket.
External identifiers
Sources: HGNC HGNC:6877 (approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)); UniProt P27361 (protein name, function text, keywords and locations (REST API)); Open Targets ENSG00000102882 (association with cancer (MONDO_0004992) 0.63; (GraphQL API, CC0))
Biology
Serine/threonine kinase which acts as an essential component of the MAP kinase signal transduction pathway. MAPK1/ERK2 and MAPK3/ERK1 are the 2 MAPKs which play an important role in the MAPK/ERK cascade. They participate also in a signalling cascade initiated by activated KIT and KITLG/SCF. Depending on the cellular context, the MAPK/ERK cascade mediates diverse biological functions such as cell growth, adhesion, survival and differentiation through the regulation of transcription, translation, cytoskeletal rearrangements. The MAPK/ERK cascade also plays a role in initiation and regulation of meiosis, mitosis, and postmitotic functions in differentiated cells by phosphorylating a number of transcription factors. About 160 substrates have already been discovered for ERKs. Location: Cytoplasm; Nucleus; Membrane, caveola; Cell junction, focal adhesion (UniProt). Locus 16p11.2 (HGNC).
Notes
top- Written by scripts/fetch-cancer-genes.ts from CIViC, Open Targets, IntOGen, HGNC and UniProt; the function text is UniProt's, condensed and in UK spelling. Roles: Open Targets known-drug datatype score 0.19. Evidence tier "clinical-evidence" is the strongest of those signals.
- Prevalence not recorded: none of the sources gives a positivity rate.
Latest papers
topQuery for this target: (TITLE:"MAPK3" OR ABSTRACT:"MAPK3" OR TITLE:"mitogen-activated protein kinase 3" OR ABSTRACT:"mitogen-activated protein kinase 3" OR TITLE:"Mitogen-activated protein kinase 3" OR ABSTRACT:"Mitogen-activated protein kinase 3" OR TITLE:"ERK1" OR ABSTRACT:"ERK1" OR TITLE:"p44mapk" OR ABSTRACT:"p44mapk" OR TITLE:"p44erk1" OR ABSTRACT:"p44erk1") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about MAPK3, not a curated reading list.